{
    "clinical_study": {
        "@rank": "119475", 
        "arm_group": {
            "arm_group_label": "autologous platelet concentrate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness of intravitreal autologous\n      platelet concentrate (APC) injection during the surgery for refractory macular holes."
        }, 
        "brief_title": "The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes", 
        "condition": [
            "Macular Hole With High Myopia (Spherical Equivalent \u2264 -6.0 Diopters) or,", 
            "Large Size Macular Hole (Diameter > 600 Microns) or", 
            "Recurred or Failed Macular Hole From Previous Surgery", 
            "or Chronic Macular Hole (Symptom Duration > 6 Months)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Retinal Perforations", 
                "Myopia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Macular hole with any of following condition\n\n               -  High myopia (spherical equivalent \u2264 -6.0 Diopters)\n\n               -  Large size macular hole (Diameter > 600 microns)\n\n               -  Recurred or failed macular hole from previous surgery\n\n               -  Chronic macular hole (symptom duration > 6 months)\n\n        Exclusion Criteria:\n\n          -  Systemic infection\n\n          -  Hematologic disease\n\n          -  Severe maculopathy including severe diabetic retinopathy, advanced age-related\n             macular degeneration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081170", 
            "org_study_id": "2013-12-066"
        }, 
        "intervention": {
            "arm_group_label": "autologous platelet concentrate", 
            "description": "pars plana vitrectomy\ninternal limiting membrane removal\nFluid-air exchange\nIntravitreal autologous platelet concentrate injection\nIntravitreal gas (14% C3F8) injection\nKeep prone position for 7-14 days after surgery", 
            "intervention_name": "Autologous platelet concentrate", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "last_name": "Se Woong Kang, MD", 
                "phone": "+82-2-3410-3562"
            }, 
            "contact_backup": {
                "last_name": "Ga Eun Cho, MD", 
                "phone": "+82-2-3410-3548"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "0000"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Se Woong Kang, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ga Eun Cho, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "last_name": "Ga Eun Cho, MD", 
            "phone": "+82-3410-3548"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "macular hole closure", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "best-corrected visual acuity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "metamorphopsia score", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "frequency and severity of ocular adverse event", 
                "measure": "safety outcome", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}